TNXP Stock Analysis
TN
Uncovered
Tonix Pharmaceuticals Holding Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. Its portfolio consists of central nervous system (CNS), rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases and cancer. Its infectious disease portfolio includes a vaccine in development to prevent smallpox and mpox, vaccines to prevent COVID-19, a platform to make fully human monoclonal antibodies (mAbs), to treat COVID-19 and humanized anti-SARS-CoV-2 mAbs. Its rare disease portfolio focuses on developing novel therapies for patients with rare diseases. Its product candidates include TNX-102 SL, TNX-102 SL, TNX-1900, TNX-601 ER and others.